GO
Loading...

Enter multiple symbols separated by commas

Search results for "JNJ"

REFINE RESULTS

SEARCH RESULTS

About 57 results. Sort By: Date | Relevance
California Assembly advances ban on microbeads in cosmetics

SACRAMENTO, Calif.- The California Assembly on Friday approved one of the nation's toughest bans on plastic, exfoliating microbeads that are polluting waterways. Manufacturers already have pledged to phase out the materials, including L'Oreal, Unilever and Johnson& Johnson, and use natural alternatives such as apricot shells and cocoa beans.
Source: The Associated Press | By: By FENIT NIRAPPIL, Associated Press
Condom company in sticky situation over lube deal

Reckitt Benckiser's planned purchase of a leading personal lubricant brand has come under scrutiny by a competition authority.
Source: CNBC.com | By: Katrina Bishop
Stocks across all generations  

According to TD Ameritrade Apple is the most widely held stock among all generations.
Source: CNBC.com
Abbvie specifies breakdown of $21 billion Pharmacyclics deal

NEW YORK- Abbvie Inc. specified the stock and cash breakdown on Thursday of its previously announced $21 billion buyout of Pharmacyclics Inc.. The drugmaker said the mixed consideration will consist of $152.25 in cash and 1.6639 shares of AbbVie common stock and, subject to proration, the all-stock consideration will consist of 3.9879 shares of AbbVie...
Source: The Associated Press
Johnson & Johnson meets investors  

Johnson & Johnson outlines a strategy to revive growth at its analyst meeting.
Source: CNBC.com
CVS paying $10.4B in cash for drug distributor Omnicare

CVS Health will pay more than $10 billion for pharmaceutical distributor Omnicare in a deal primed to feed its fast-growing specialty drug business and tap a lucrative and growing market: care for the elderly. Omnicare's long-term care business operates in 47 states and the District of Columbia. Cincinnati- based Omnicare's core business involves...
Source: The Associated Press
Stocks fall from highs, end mixed after Fed minutes; transports off nearly 2%

U.S. stocks closed narrowly mixed as the Fed minutes mostly confirmed market expectations for a rate hike in the second half of the year.
Source: CNBC.com | By: Evelyn Cheng
The hep C challenge  

Analysts tend to leave out Johnson & Johnson's hepatitis C drug out of the company's growth projections. Details, with NBC's Meg Tirrell.
Source: CNBC.com
UPDATE 2-J&J to submit at least 10 new drugs for approval by 2019

May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United...
Source: Reuters | By: Bill Berkrot and Caroline Humer
How biotechs are affecting J&J's business  

Michael Weinstein, JPM, managing director of healthcare, joins CNBC's Meg Tirrell to discuss biosimilar, the threat to big pharmaceuticals, and how Johnson & Johnson will be affected.
Source: CNBC.com